Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2024
Filed with the SEC on Mar 15, 2024 and accepted by EDGAR at Mar 14, 2024, 21:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-11-01 to 2024-01-31 | $12.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-05-01 to 2024-01-31 | $36.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-11-01 to 2024-01-31 | $7.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-05-01 to 2024-01-31 | $22.2m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-11-01 to 2024-01-31 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-05-01 to 2024-01-31 | $7.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-11-01 to 2024-01-31 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-05-01 to 2024-01-31 | −$7.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-11-01 to 2024-01-31 | $11.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-05-01 to 2024-01-31 | $49.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-11-01 to 2024-01-31 | −$2.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-05-01 to 2024-01-31 | −$7.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-11-01 to 2024-01-31 | −$0.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-05-01 to 2024-01-31 | −$0.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-11-01 to 2024-01-31 | −$0.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-05-01 to 2024-01-31 | −$0.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-11-01 to 2024-01-31 | 13,593,758 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-05-01 to 2024-01-31 | 13,538,480 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-05-01 to 2024-01-31 | −$4.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-05-01 to 2024-01-31 | $947.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2023-05-01 to 2024-01-31 | $634.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-01-31 | $4.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-01-31 | $13.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-01-31 | $26.8m | us-gaap:Assets |
| Current liabilities | At period end2024-01-31 | $22.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-01-31 | $28.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-01-31 | −$2.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-011279. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.